We propose to conduct a case-control study of carcinoma in situ of the breast to be conducted in parallel with the Carolina Breast Cancer Study (CBCS). Participants will include women from the 24-county area of central and eastern North Carolina covered by the CBCS. Cases will include all women with a first diagnosis of carcinoma in situ (DCIS or LCIS) between 9/1/95 and 2/28/00 identified through the Central Cancer Registry rapid- ascertainment system developed for the CBCS. Based upon preliminary data collected during 1993, we expect 400 cases within the accrual period. Comparison subjects (controls) will consist of an equal number of women without a history of in-situ (or invasive) breast disease, frequency matched to cases based upon expected distributions by age (+/- 5 years) and race. Controls will be identified using DMV and/or HCFA records. Once a potential control has been contacted, any women who have not undergone mammography within a one year period prior to selection will be offered mammography at an institutional rate through UNC hospitals. Information on established and hypothesized risk factors for breast cancer will be obtained by personal interview using the questionnaire for the CBCS. Blood samples for extraction of germline DNA will be obtained from consenting participants, and paraffin-embedded tumor specimens and medical records will be requested for all cases. The research objectives are: (1) To identify risk factors for occurrence of DCIS and LCIS of the breast; (2) To determine whether differences in histologic appearance as well as immunohistochemical and molecular profiles of in situ lesions reflect differences in underlying etiology (i.e. exposure to specific risk factors for breast cancer); (3) To specifically evaluate the contributions of tobacco smoking and chlorinated hydrocarbon pesticides, as well as other exposures in which a study of precursor lesions is expected to have advantages over previous epidemiologic studies employing invasive breast cancer as the sole endpoint; (4) To compare cases of in-situ carcinoma in African American to Caucasian women in order to determine whether the mutational spectrum, histologic characteristics, or results of other biologic assays suggest a different (possibly more aggressive) form of breast cancer in African- American women; (5) To determine whether mutations in BRCA1, BRCA2, and other loci of inherited susceptibility represent risk factors for occurrence of in-situ carcinoma of the breast. The proposed study will benefit from utilizing the same infrastructure as the CBCS, and will involve the same group of investigators and support personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-07
Application #
6102862
Study Section
Project Start
1998-08-05
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304

Showing the most recent 10 out of 598 publications